TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02714257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care plus Exercise Coaching
Description: For month one of the exercise intervention the investigators will conduct only strength and a few balance exercises to rehabilitate the participants. After the first month, and once the participants feel comfortable, the investigators will incorporate aerobic and additional balance exercises. The investigators will personalize participant programs based on baseline levels and increase them gradually. The exercise session will be conducted 50 minutes 3 times a week. Between sets there is a 60-second break.~Every month the coach will record steps from the pedometer and record patient adherence to exercise sessions, and every 2 months the coach will measure strength and will track resistance band color from the exercise trackers.~For the individuals exercising at home, the investigators will distribute the exercise Digital Versatile Disc (DVDs) every 9 months and the coach will continue to contact them, just as if they were joining the group. Coaches will encourage group participation.
Study: NCT04578886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: Guanfacine 2 mg administered at 21:00 for up to 14 days or otherwise indicated by study protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, administered at 2100 for up to 14 days or otherwise indicated by study protocol.
Study: NCT03020238

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: BiClamp group
Description: electric energy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water jet group
Description: water jet energy
Study: NCT01028950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study: NCT01638091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ex vivo module
Description: Pre-test, ex vivo computerized training module, post-test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In vivo practice-base learning phase
Description: Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
Study: NCT03407651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa variant
Description: Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa variant
Description: Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa variant
Description: Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.
Study: NCT03392272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using of Tisseel fibrin glue
Description: Using of Tisseel fibrin glue instead of sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Using sutures
Description: Using sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
Study: NCT04695392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R2 Bundle
Description: During the intervention phase subjects will receive R2.~1. Focused effort to replicate the child's pre-hospitalization daily routine (bedtime/wake time, bedtime/arousal routine, nap time, feeding schedule, active periods),~2. Cycled day-night lighting and modulation of sound to match the child's routine,~3. Minimal yet effective sedation using a nurse-implemented goal-directed sedation plan (RESTORE),~4. Night fasting with bolus enteral daytime feedings,~5. Early, developmentally-appropriate, progressive exercise and mobility (PICU Up!),~6. Continuity in nursing care, and~7. Parent diaries.
Study: NCT00521053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PV-10 (10% rose bengal disodium)
Description: Intralesional injection for chemoablation
Study: NCT04286425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: seminal plasma
Description: Seminal plasma free of sperm, from donor men with normal sperm parameters, and tested for HIV1, HIV2, Hepatitis B, Hepatitis C, Syphilis, Chlamydia and Gonorrhea on blood and urine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: saline solution
Study: NCT01034540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POM3
Description: 4 g/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule, 4 g/day
Study: NCT04115826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Per-oral Pancreatoscopy-guided Lithotripsy
Description: Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extracorporeal Shock-Wave Lithotripsy
Description: ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
Study: NCT03663881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Et extract
Description: P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
Study: NCT02465385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
Study: NCT02149212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotonic
Description: Aminaftone -- 75 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phlebotonic
Description: Aminaftone -- 75 mg BID

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Iliac Vein Stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limb elastic compression support
Description: CEAP 3-5 \> 20-30 mmHg compression stockings CEAP 6 \> elastic bandages

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limb elastic compression support
Description: CEAP 3-5 \> 20-30 mmHg compression stockings CEAP 6 \> elastic bandages

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unna boot dressing
Description: CEAP 6 \> Unna boot dressing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unna boot dressing
Description: CEAP 6 \> Unna boot dressing
Study: NCT03759483

Intervention type: DIAGNOSTIC_TEST
Intervention: AI diagnostic algorithm
Description: The visual fields collected would be assessed by the algorithm and ophthalmologists independently. The performance of the algorithm and the ophthalmologists would be compared, including accuracy, AUC, sensitivity and specificity.
Study: NCT04607928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
Study: NCT04420650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal or cathodal transcranial direct current stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal or cathodal transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal or cathodal transcranial direct current stimulation
Study: NCT04688723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran + Ticagrelor
Description: Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran + clopidogrel
Description: Patiënt interventional treatment, with dabigatran + clopidogrel (plavix) 75mg once daily up to 12 months.
Study: NCT03005951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A= Yes Breakfast
Description: Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when given breakfast and lunch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A= Yes Breakfast
Description: Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when given breakfast and lunch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B=No Breakfast
Description: Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when breakfast is skipped and lunch is provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B=No Breakfast
Description: Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when breakfast is skipped and lunch is provided.
Study: NCT00613054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zactima, Gleevec, Hydroxyurea
Description: Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate \& hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs \& 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate \& that such doses are safe \& well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety \& pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate \& hydroxyurea for 28 days for purpose of scheduling evaluations.
Study: NCT01252810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-145
Description: GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GE-145
Description: GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
Study: NCT00636467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No name
Description: Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
Study: NCT02885194

Intervention type: OTHER
Group type: OTHER
Intervention: Laser-Evoked potential
Description: Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
Study: NCT02304848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS (Deep Brain Stimulation)
Description: Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
Study: NCT02347488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Haider ETT Tube Holder and Bite Guard
Description: Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tape
Description: Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
Study: NCT00686296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taliderm™
Description: taliderm™ dressing application once

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taliderm™
Description: Taliderm™ dressing application up to three applications

Intervention type: OTHER
Group type: OTHER
Intervention: standard wet to dry dressing with gauze
Description: wet to dry dressing standard of care
Study: NCT01167751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNC
Description: Implantation of BM derived MNC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AC 133
Description: Implantation of BM derived AC133

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Injection of cell carrier
Study: NCT00792454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.~Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.~Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet.
Study: NCT02448693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WLE
Description: Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WLE
Description: Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI
Description: Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI
Description: Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).
Study: NCT01162239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid. Participants in the Extended Relapse Prevention plus varenicline will receive varenicline for up to 40 additional weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial Individual counseling
Description: Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial Individual counseling
Description: Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial Individual counseling
Description: Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial Individual counseling
Description: Five 90 minute individual counseling sessions to occur during the first 12 weeks of initial treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check-ins with medical staff
Description: Monthly brief (10-15 minutes) meetings with medical staff.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Individual Counseling - Health Model
Description: Monthly counseling sessions across a nine month period with content based on a health education model. Each session is 30-45 minutes in duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Individual Counseling - Relapse Prevention Model
Description: Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Individual Counseling - Relapse Prevention Model
Description: Eleven individual counseling sessions across a nine month period with content based on a relapse prevention model. Each session is 30-45 minutes in duration.
Study: NCT02204384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFD Meal: High fiber from food
Description: High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HFS Meal: High fiber from supplement
Description: High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UF Meal: usual amount of fiber
Description: Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
Study: NCT02568475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of Go to the Hospital or Stay Here?
Description: Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
Study: NCT01298583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ankle tracking training
Description: one group will use the ankle for tracking, the other group will use the ankle for simple movement
Study: NCT00417040

Intervention type: OTHER
Group type: OTHER
Intervention: internet-based intervention
Description: Use the STAR database system

Intervention type: OTHER
Group type: OTHER
Intervention: assessment of therapy complications
Description: Use the STAR database system

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04136184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inotersen
Description: Inotersen by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplontersen
Description: Eplontersen by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplontersen
Description: Eplontersen by subcutaneous injection
Study: NCT02780674

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI7734
Description: Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
Study: NCT04454437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously
Study: NCT02575404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR-MD-02
Description: Patients will receive five doses of GR-MD-02 intravenously over 85 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR-MD-02
Description: Patients will receive five doses of GR-MD-02 intravenously over 85 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR-MD-02
Description: Patients will receive five doses of GR-MD-02 intravenously over 85 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR-MD-02
Description: Patients will receive five doses of GR-MD-02 intravenously over 85 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.